Prevnar 13 Approval History
- FDA approved: Yes (First approved February 24th, 2010)
- Brand name: Prevnar 13
- Generic name: pneumococcal 13-valent conjugate vaccine
- Company: Wyeth Pharmaceuticals Inc.
- Treatment for: Pneumococcal Disease Prophylaxis
Prevnar 13 (pneumococcal 13-valent conjugate vaccine) is a vaccine indicated for active immunization against invasive pneumococcal disease in infants, young children and adults ages 50 and older.
Development History and FDA Approval Process for Prevnar 13
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.